In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(CH)2 vitamin D3

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1770-1776

  Hirata, Michinori ^a   Katsumata, Kyoko ^a   Endo, Koichi ^a   Fukushima, Naoshi ^a   Ohkawa, Hiroyuki ^a   Fukagawa, Masafumi ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,25(OH )2D3; 22 oxacalcitriol; Ca x Pi product; Metastatic calcification

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA DISEASE; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; HEART DISEASE; HORMONE INHIBITION; KIDNEY CALCIFICATION; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; NONHUMAN; PARTIAL NEPHRECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; CALCINOSIS; CALCITRIOL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; KIDNEY; KIDNEY DISEASES; MALE; NEPHRECTOMY; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY; VITAMINS;

EID: 0042384999     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg296     Document Type: Article

References (20)

1. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
2. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392
3. Guérin AP, London GM, Marfhais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
4. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
5. Kimura K, Saika Y, Otani H et al. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 1999; 56: S238-S241
6. Lau K. Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int 1989; 36: 918-937
7. Hruska KA, Goligorsky M, Scoble J et al. Effects of parathyroid hormone on cytosolic calcium in renal proximal tubular primary cultures. Am J Physiol 1986; 251: F188-F198
8. 3 with an oxygen atom in the side chain skeleton: a trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia. FEBS Lett 1987; 226: 58-62
9. 3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43: 561-566
10. Hirata M, Katsumata K, Masaki T et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999; 56: 2040-2047
11. Monier-Faugere M-C, Geng Z, Friedler RM et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55: 821-832
12. Planells E, Llopis J, Peran F, Aranda P. Changes in tissue calcium and phosphorus content and plasma concentrations of parathyroid hormone and calcitonin after long-term magnesium deficiency in rats. J Am Coll Nutr 1995; 14, 292-298
13. Ichikawa F, Hirata M, Endo K et al. Attenuated up- regulation of vitamin D-dependent calcium-binding proteins by 22-oxa-1,25-dihydroxyvitamin D3 in uremic rats: a possible mechanism for less-calcemic action. Nephrology 1998; 4: 391-395
14. Hirata M, Endo K, Katsumata K et al. A comparison between 1,25- dihydroxy- 22- oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 41-45
15. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306
16. Jono S, Mckee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res 2000; 87: e10-e17
17. Dusso AS, Negrea L, Gunawardhana S et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991; 128: 1687-1692
18. 3H]-1,25-dihydroxyvitamin D3, determined by micro-autoradiography. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 53-57
19. Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant, 2002; 17: 723-731
20. Kenner CH, Evan AP, Blomgren P, Aronpff GR, Luft FC. Effect of protein intake on renal function and structure in partially nephrectomized rats. Kidney Int 1985; 27: 739-750